EcoDrugPlus

Tubulin Alpha 1c

Ensembl ID : ENSBTAG00000039992
Gene Symbol: TUBA1C
4 Cross references
127 Possible Orthologues:

Tubulin Alpha 3c

Ensembl ID : ENSBTAG00000038258
Gene Symbol: TUBA3C
57 Enzyme and pathways 5 Cross references
120 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSBTAG00000030974
Gene Symbol: TUBA4A
67 Enzyme and pathways 5 Cross references
237 Possible Orthologues:

Tubulin Alpha-1c Chain-Like

Ensembl ID : ENSBTAG00000037775
Gene Symbol: LOC100141266
57 Enzyme and pathways 4 Cross references
123 Possible Orthologues:

Tubulin Alpha-1c Chain-Like

Ensembl ID : ENSBTAG00000040518
Gene Symbol: LOC112443216
4 Cross references
127 Possible Orthologues:

Tubulin Beta 1 Class Vi

Ensembl ID : ENSBTAG00000018785
Gene Symbol: TUBB1
57 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Tubulin Beta 2a Class Iia

Ensembl ID : ENSBTAG00000048485
Gene Symbol: TUBB2A
57 Enzyme and pathways 5 Cross references
241 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSBTAG00000023730
Gene Symbol: TUBB3
57 Enzyme and pathways 5 Cross references
166 Possible Orthologues:

Tubulin Beta 4a Class Iva

Ensembl ID : ENSBTAG00000021013
Gene Symbol: TUBB4A
64 Enzyme and pathways 5 Cross references
101 Possible Orthologues:

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSBTAG00000052518
Gene Symbol: TUBB4B
66 Enzyme and pathways 4 Cross references
189 Possible Orthologues:

Tubulin Beta 6 Class V

Ensembl ID : ENSBTAG00000046337
Gene Symbol: TUBB6
57 Enzyme and pathways 5 Cross references
153 Possible Orthologues:

Tubulin Beta Class I

Ensembl ID : ENSBTAG00000006969
Gene Symbol: TUBB
19 Enzyme and pathways 5 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).